SSX2 and neoplasm: Recently, Kadoch described the high-affinity binding of SS18/SSX fusion to the core subunits of the SWI/SNF (BAF) complex and SS18 and SS18/SSX incorporate into the core subunits of SWI/SNF (BAF) complex, by dissociating BAF47 from the complex, thereby releasing SNF5, a tumor suppressor [43].